Jason Paul Steik Insider Profile
4 Followers
Jason Paul Steik, Chief Clinical Officer at Pennant Group, holds 15.11K shares in Pennant Group (Ticker: PNTG). Most recently, Jason Paul Steik Sold 1,394 shares of Pennant Group on Aug 10, 2026 for an estimated value of $53.70K.
Jason Paul Steik has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of Jason Paul Steik's holdings
Insider Roles
Chief Clinical Officer
Roles that Jason Paul Steik holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Jason Paul Steik
Jason Paul Steik's Trading History
List of latest transactions for each holding click on a transaction to see Jason Paul Steik's performance on stock
You May Also Like
Jason Paul Steik insider profile FAQ
What is the percentage of profitable transactions made by Jason Paul Steik?
The percentage of profitable transactions made by Jason Paul Steik is ―.
What is the average return per transaction made by Jason Paul Steik?
The average return per transaction made by Jason Paul Steik is ―.
What stocks does Jason Paul Steik hold?
Jason Paul Steik holds: PNTG stocks.
What was Jason Paul Steik’s latest transaction?
Jason Paul Steik latest transaction was an Informative Sell of $53.70K.
What was Jason Paul Steik's most profitable transaction?
Jason Paul Steik’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Jason Paul Steik's role in Pennant Group?
Jason Paul Steik's role in Pennant Group is Chief Clinical Officer.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.